Skip to main content
Download PDF

Pharmacokinetic Parameters of Oral Pegylated IFN-λ1

Bulletin of Experimental Biology and Medicine volume 173, pages 215–218 (2022)Cite this article

We studied the pharmacokinetics of a pegylated IFN-λ1 (PEG IFN-λ1) after its oral administration to rats in different therapeutic doses. The hypothesis on linear pharmacokinetics of PEG IFN-λ1 within the dose range of 2.6-7.8 μg/kg was confirmed, high for protein molecules bioavailability from 17.5 to 21%, the absence of intravascular deposition, and effective elimination with feces and urine (85 and 15% of the administered dose, respectively) were demonstrated. At the same time, the mean retention time for PEG IFN-λ1 in the circulation is 6.46-6.65 h and half-life is 3 h. These findings give ground for continuing experimental studies of PEG IFN-λ1 pharmacokinetics, in particular, tissue distribution of the drug.

References

  1. Grigoryan SS. Interferon lambda (type 3 interferons) and viral infections. Interferon — 2011. Ershova FI, Narovlyansky AN, eds. Moscow, 2012. P. 63-72. Russian.

  2. Karkischenko NN, Khoron’ko VV, Sergeeva SA, Karkischenko VN. Pharmacokinetics. Dolzhich GI, ed. Rostov-on-Don, 2001. Russian.

  3. Kikhtenko NA, Ilyicheva TN, Durymanov AG, Fursova AZh, Madonov PG. Investigation of the antiviral activity of the recombinant human interferon lambda 1 in human conjunctiva cell culture. Sib. Nauch. Med. Zh. 2021;41(5):31-36. doi: https://doi.org/10.18699/SSMJ20210504.Russian.

    Article  Google Scholar 

  4. Madonov PG, Kikhtenko NA, Oleinik LA, Udut VV. Interferon Lambda — the new representative of pharmacologically active interferons. Eksp. Klin. Farmakol. 2020;83(6):30-37. doi: https://doi.org/10.30906/0869-2092-2020-83-6-30-37.Russian.

    CAS  Article  Google Scholar 

  5. Madonov PG, Svyatchenko VA, Legostaev SS, Kikhtenko NA, Kotlyarova AA, Oleinik LA, Baikalov GI. Evaluation of the Anti-Viral Activity of Human Recombinant Interferon Lambda-1 against SARS-CoV-2. Bull. Exp. Biol. Med. 2021;172(1):53-56. doi: https://doi.org/10.1007/s10517-021-05330-0

    CAS  Article  PubMed  Google Scholar 

  6. Madonov PG, Svyatchenko VA, Legostaev SS, Kikhtenko NA, Kotlyarova AA, Oleinik LA, Baikalov GI, Udut VV. Antiviral activity against SARS-CoV-2 of a pharmaceutical substance based on immobilized recombinant human interferon lambda-1. Eksp. Klin. Farmakol. 2021;84(7):15-20. doi: https://doi.org/10.30906/0869-2092-2021-84-7-15-20.Russian.

    Article  Google Scholar 

  7. Metelsky ST. Transport Processes and Membrane Digestion in the Small Intestinal Mucosa. Electrophysiological Model. Moscow, 2007. Russian.

    Google Scholar 

  8. Miroshnichenko II. Basics in Pharmacokinetics. Moscow, 2002. Russian.

    Google Scholar 

  9. Petrie A, Sabin C. Medical Statistics at a Glance. Moscow, 2021.

  10. Piotrovsky VK. The method of statistical moments and integral model-independent parameters of pharmacokinetics. Farmakol. Toksikol. 1986;49(5):118-127. Russian.

    Google Scholar 

  11. Manual for Preclinical Studies of New Pharmacological Substances. Part I, Mironov AN, ed. Moscow, 2012. Russian.

  12. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003;4(1):69-77. doi: https://doi.org/10.1038/ni875

    CAS  Article  PubMed  Google Scholar 

  13. Lazear HM, Schoggins JW, Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity. 2019;50(4):907-923. doi: https://doi.org/10.1016/j.immuni.2019.03.025

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003;4(1):63-68. doi: https://doi.org/10.1038/ni873

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia

    E. Yu. Sherstoboev & V. V. Zhdanov

  2. Research Institute of Clinical and Experimental Lymphology — Affiliated Branch of Federal Research Center Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia

    L. A. Oleinik, N. A. Kikhtenko & P. G. Madonov

Authors
  1. E. Yu. Sherstoboev
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. A. Oleinik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. V. Zhdanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. A. Kikhtenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. G. Madonov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Yu. Sherstoboev.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 173, No. 2, pp. 188-192, February, 2022

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sherstoboev, E.Y., Oleinik, L.A., Zhdanov, V.V. et al. Pharmacokinetic Parameters of Oral Pegylated IFN-λ1. Bull Exp Biol Med 173, 215–218 (2022). https://doi.org/10.1007/s10517-022-05521-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-022-05521-3

Key Words

  • interferon lambda
  • pegylated interferon lambda 1 (PEG IFN-λ1)
  • pharmacokinetic